More News! Lurid Pharma Stories, Money & Partnerships

Try as we might, we can’t cover all the biotech news out there, especially with the holiday madness only just behind us! Here’s a roundup of news that didn’t make the cut.


  • Merus has partnered with IRB in Barcelona to develop tumor microenvironment antibodies
  • Phenex took home a $100M milestone from Gilead for its FXR agonist results
  • Allergan is making good on its promise not to hike prices by more than 10% this year
  • Affimed has joined MD Anderson’s long list of partners in an immuno-oncology deal
  • HepaRegeniX reeled in €9M in Series A to treat chronic liver diseases with kinase inhibitors


  • A JNK inhibitor from Xigen is performing well in Phase II
  • Saniona‘s Tesomet is delivering positive results for type 2 diabetes in Phase II
  • AB Science stumbled upon a drug that protects muscles and nerves in amyotrophic lateral sclerosis.


  • Pharma started the year with a busy week, and it culminated in a suicide attempt by a Novartis exec.
  • Sanofi backed down from a patent battle with Amgen, sued Novo Nordisk, and retracted vaccine ads after a C&D from the FDA of the Philippines.
  • Medigene spun out a new daughter company in Sweden making moves in cell and immunotherapy.

Cat or Dulce de Leche?


Images from Brian Lasenby, Galka, Sjstudio6, Quinn Martin /

Support good journalism, subscribe to Labiotech Insider

Labiotech Insider

If you liked this post and want to read more good journalism, support us by joining Labiotech Insider. Our Insider membership gives you access to exclusive content and other advantages.